Robalzotan AstraZeneca.
AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a predicted launch date of 2005 [384880].
h.mucke@aon.at
H A
HA
Mucke
D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D001578:Benzopyrans / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D015507:Drugs, Investigational / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy; D010330:Patents as Topic; D012702:Serotonin Antagonists / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D014151:Anti-Anxiety Agents; D001578:Benzopyrans; D015507:Drugs, Investigational; D012702:Serotonin Antagonists; C108607:robalzotan